WEST PHARMACEUTICAL SERVICES INC 8-K

What Happened West Pharmaceutical Services, Inc. announced that it and Daikyo Seiko, Ltd. entered into an Amended and Restated Technology Exchange and Crosslicense Agreement and two Distributorship Agreements effective July 14, 2026. West holds a 49% ownership interest in Daikyo. The new agreements largely restate and extend the parties’ prior arrangements (originally dated January 18, 2017, with later amendments) and govern sharing of know‑how, patents and trademarks, joint development, and product distribution for closures, vials, cartridges, syringes and related device components used with pharmaceutical products.

Key Details

• Effective date: July 14, 2026; each Agreement has a 10‑year term.
• Ownership: West maintains a 49% stake in Daikyo.
• Licensing: Daikyo’s license from West is non‑exclusive; West’s license from Daikyo is exclusive outside Japan (subject to limited exceptions).
• Distribution: West is the exclusive distributor of Daikyo products outside Japan (with limited exceptions); Daikyo is a non‑exclusive distributor of West products in Japan.
• Royalties/fees: Crosslicense is generally royalty‑free except for a fixed royalty rate applicable to certain patents and non‑patented technical information.
• Termination: Agreements can be ended early in specified circumstances (including mutual consent or a change in control); if the crosslicense is terminated, parties will negotiate post‑termination use terms.

Why It Matters These agreements formalize long‑term commercial and intellectual property cooperation between West and Daikyo, securing distribution rights and IP sharing for key drug‑packaging and delivery components for the next decade. For investors, the deals preserve West’s commercial access and technology collaboration outside Japan (and Daikyo’s access within Japan), which can affect product availability, competitive positioning and potential revenue streams tied to these products. The filing does not disclose specific financial payments beyond the limited royalty framework; full, redacted agreement texts will be filed as exhibits to West’s Form 10‑Q for the quarter ending September 30, 2026.